课题基金 / 基金详情

SYNTHESIS OF CERTAIN AZOLO [1,3] OXAZINE NUCLEOSIDES

SYNTHESIS OF CERTAIN AZOLO [1,3] OXAZINE NUCLEOSIDES
某些偶氮[1,3]恶嗪核苷的合成
批准号:
3168124
负责人:
LEROY B. TOWNSEND
金额:
$11.46万
依托单位国家:
美国
项目类别:
财政年份:
1980
资助国家:
美国
项目状态:
已结题
起止时间:
1980-08-01 至 1987-06-30

项目摘要

项目成果

LEROY B. TOWNSEND的其他基金

相似基金

相关文献

中文摘要
翻译
拟议研究的目标将是综合某些 双环二唑并[1,3]恶嗪核苷 核苷 这项研究将提供类似的自然发生的 核苷(肌苷,腺苷,鸟苷和黄苷),然后将 作为腺苷酶的底物和/或抑制剂进行试验 脱氨酶,腺苷激酶,嘌呤核苷磷酸化酶 (PNTR)和次黄嘌呤-鸟嘌呤磷酸核糖基转移酶(HGPRT酶)。 如有必要,将合成其他衍生物, 建立构效关系。 物理化学研究 包括互变异构形式、pKa等,将致力于 将这些因素中的一些与它们的生物学和化学治疗相关联 活动 这些核苷也将作为抗癌剂进行评价 体外(内部)和体内(NCI)。 还将进行研究 为了确定这些核苷是否像嘌呤一样 化合物、嘧啶样化合物或可能作为药物的前药。 我们将用它作为我们的起始原料。
英文摘要
The objective of the proposed research will be to synthesize certain bicyclic diazolo[1,3]oxazine nucleosides from the appropriate monocyclic nucleosides. This study will provide analogs of the naturally occurring nucleosides (inosine, adenosine, guanosine and xanthosine), which will then be tested as substrates and/or inhibitors of the enzymes adenosine deaminase (ADase), adenosine kinase, purine nucleoside phosphorylase (PNPase), and hypoxanthine-guanine phosphoribosyltransferase (HGPRTase). Additional derivatives will be synthesized as deemed necessary in order to establish a structure activity relationship. Physico-chemical studies involving tautomeric forms, pKa's, etc., will be undertaken in efforts to correlate some of these factors with their biological and chemotherapeutic activity. These nucleosides will also be evaluated as anticancer agents both in vitro (in house) and in vivo (NCI). Studies will also be conducted in order to determine if these nucleosides are acting as purine-like compounds, pyrimidine-like compounds or perhaps as a pro-drug of the monocyclic nucleosides which we will be using as our starting materials.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
NEW HETEROCYCLES AND NUCLEOSIDES AS INHIBITORS OF HCMV
NEW HETEROCYCLES AND NUCLEOSIDES AS INHIBITORS OF HCMV
NEW HETEROCYCLES AND NUCLEOSIDES AS INHIBITORS OF HCMV
HETEROCYCLIC COMPOUNDS AS SELECTIVE INHIBITORS OF HUMAN CYTOMEGALOVIRUS
海外基金